Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Harjit Dumra, Arjun Khanna, Sujeet K Madhukar, Meena Lopez & Jaideep Gogtay. (2022) Perceptions and Attitudes of Patients and Their Family Caregivers on Nebulization Therapy for COPD. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2277-2288.
Read now
Read now
Jill A Ohar, Gary T Ferguson, Donald A Mahler, M Bradley Drummond, Rajiv Dhand, Roy A Pleasants, Antonio Anzueto, David M G Halpin, David B Price, Gail S Drescher, Haley M Hoy, John Haughney, Michael W Hess & Omar S Usmani. (2022) Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 79-92.
Read now
Read now
Xiaoli Niu, Victoria Divino, Sanjay Sharma, Mitch Dekoven, Vamshi Ruthwik Anupindi & Carole Dembek. (2021) Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with nebulized glycopyrrolate in the USA: a real-world data analysis. Journal of Medical Economics 24:1, pages 1-9.
Read now
Read now
Hanan M. El-Laithy, Amal Youssef, Shereen S. El-Husseney, Nesrine S. El Sayed & Ahmed Maher. (2021) Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks. Drug Delivery 28:1, pages 826-843.
Read now
Read now
Judith J Stephenson, Carole Dembek, Amanda Caldwell-Tarr, Rebecca M Conto, Mark Paullin & Edward M Kerwin. (2020) Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1713-1727.
Read now
Read now
Collin M Clark, David M Jacobs & Sanjay Sethi. (2020) Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 14:3, pages 239-247.
Read now
Read now
Marie T Borin, Arthur Lo, Chris N Barnes, Srikanth Pendyala & David L Bourdet. (2019) Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2305-2318.
Read now
Read now
Bartolome R Celli, Maryam Navaie, Zhun Xu, Soojin Cho-Reyes, Carole Dembek & Todd P Gilmer. (2019) Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1019-1031.
Read now
Read now
Jill Ohar, Robert Tosiello, Thomas Goodin & Shahin Sanjar. (2019) Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 27-37.
Read now
Read now
James F Donohue, Donald A Mahler & Sanjay Sethi. (2019) Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2947-2958.
Read now
Read now
Michael DePietro, Ileen Gilbert, Lauren A. Millette & Michael Riebe. (2018) Inhalation device options for the management of chronic obstructive pulmonary disease. Postgraduate Medicine 130:1, pages 83-97.
Read now
Read now
Alpesh N Amin, Vaidyanathan Ganapathy, Adam Roughley & Mark Small. (2017) Confidence in correct inhaler technique and its association with treatment adherence and health status among US patients with chronic obstructive pulmonary disease. Patient Preference and Adherence 11, pages 1205-1212.
Read now
Read now
Pierachille Santus, Dejan Radovanovic, Andrea Cristiano, Vincenzo Valenti & Maurizio Rizzi. (2017) Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease. Drug Design, Development and Therapy 11, pages 3257-3271.
Read now
Read now
Vaidyanathan Ganapathy & Michael D Stensland. (2017) Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1793-1801.
Read now
Read now
Daniel R Ouellette & Kim L Lavoie. (2017) Recognition, diagnosis, and treatment of cognitive and psychiatric disorders in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 639-650.
Read now
Read now
Ahmed Hassan, Randa Salah Eldin, Maha M. Abdelrahman & Mohamed E. Abdelrahim. (2017) In-vitro/in-vivo comparison of inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during non-invasive ventilation. Experimental Lung Research 43:1, pages 19-28.
Read now
Read now
Donald P Tashkin. (2016) A review of nebulized drug delivery in COPD. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 2585-2596.
Read now
Read now
Yaozhu J. Chen, Charles Makin, Vamsi K. Bollu, Maryam Navaie & Bartolome R. Celli. (2016) Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting 2-agonists. Journal of Medical Economics 19:1, pages 11-20.
Read now
Read now
Chris Garvey, Nicola A Hanania & Pablo Altman. (2014) Optimizing care of your patients with COPD. Nursing: Research and Reviews 4, pages 7-18.
Read now
Read now
Arzu Ari & James B Fink. (2013) Aerosol therapy in children: challenges and solutions. Expert Review of Respiratory Medicine 7:6, pages 665-672.
Read now
Read now
James B. Fink, Gene L. Colice & Rick Hodder. (2013) Inhaler Devices for Patients with COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 10:4, pages 523-535.
Read now
Read now
Vamsi Bollu, Frank R Ernst, John Karafilidis, Krithika Rajagopalan, Scott B Robinson & Sidney S Braman. (2013) Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. International Journal of Chronic Obstructive Pulmonary Disease 8, pages 631-639.
Read now
Read now
Articles from other publishers (54)
Amanda A. Foster, Jennifer Stoll, Christopher J. Daly, Collin M. Clark, Sanjay Sethi & David M. Jacobs. (2023) Patient and social factors related to nebulizer use in COPD patients at the transition of care: a qualitative study. BMC Pulmonary Medicine 23:1.
Crossref
Crossref
Paul D. Terry & Rajiv Dhand. (2023) The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD. Pulmonary Therapy.
Crossref
Crossref
Maria Gabriella Matera, Nicola A. Hanania, Mauro Maniscalco & Mario Cazzola. (2023) Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities. Drugs & Aging 40:7, pages 605-619.
Crossref
Crossref
Huizhen Yang, Yan Wang, Xiaole Chen, Baobin Sun, Feng Tao, Xiaojian Xie & Yi Zhang. (2023) The effects of temperature and humidity on the deposition of nebulized droplet in an idealized mouth-throat model. Flow Measurement and Instrumentation 91, pages 102359.
Crossref
Crossref
Xueying Xia, Ting Ding, Xiaole Chen, Feng Tao, Baobin Sun, Tong Lu, Jianwei Wang, Yu Huang & Yin Xu. (2022) Evaporation Affects the In Vitro Deposition of Nebulized Droplet in an Idealized Mouth-Throat Model. Atmosphere 14:1, pages 93.
Crossref
Crossref
Cheryl Nickerson, Dirk von HollenSara GarbinKetah DotyJeff JaskoChuck Cain. (2022) Pilot Study to Investigate the Benefits of the InnoSpire Go Mesh Nebulizer Compared to Jet Nebulizers in the Treatment of Stable COPD. Journal of Aerosol Medicine and Pulmonary Drug Delivery 35:4, pages 186-195.
Crossref
Crossref
David M. G. Halpin & Donald A. Mahler. (2022) A Systematic Review of Published Algorithms for Selecting an Inhaled Delivery System in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society 19:7, pages 1213-1220.
Crossref
Crossref
Jianwei Wang, Ya Zhang, Xiaole Chen, Yu Feng, Xiaoyong Ren, Minjuan Yang & Ting Ding. (2022) Targeted delivery of inhalable drug particles in a patient-specific tracheobronchial tree with moderate COVID-19: A numerical study. Powder Technology 405, pages 117520.
Crossref
Crossref
Hui-Yun Tseng, Hui-Ling LinHan-Sun Chiang. (2022)
In Vitro
Evaluation of Aerosol Delivery by Hand-Held Mesh Nebulizers in an Adult Spontaneous Breathing Lung Model
. Journal of Aerosol Medicine and Pulmonary Drug Delivery 35:2, pages 83-90.
Crossref
Crossref
Qomariyatus Sholihah, Dewi Hardiningtyas, Kumoro Lenggono, Stephan Adriansyah Hulukati, Wahyudi Kuncoro & Eko Tri Wisuda. (2022) Usability Prototype Smart Portable Nebulizer for Self-care with Respiratory Disorders at Home. Open Access Macedonian Journal of Medical Sciences 10:E, pages 171-176.
Crossref
Crossref
S.K. Katiyar, S.N. Gaur, R.N. Solanki, Nikhil Sarangdhar, J.C. Suri, Raj Kumar, G.C. Khilnani, Dhruva Chaudhary, Rupak Singla, Parvaiz A. Koul, Ashok A. Mahashur, A.G. Ghoshal, D. Behera, D.J. Christopher, Deepak Talwar, Dhiman Ganguly, H. Paramesh, K.B. Gupta, Mohan Kumar T, P.D. Motiani, P.S. Shankar, Rajesh Chawla, Randeep Guleria, S.K. Jindal, S.K. Luhadia, V.K. Arora, V.K. Vijayan, Abhishek Faye, Aditya Jindal, Amit K. Murar, Anand Jaiswal, Arunachalam M, A.K. Janmeja, Brijesh Prajapat, C. Ravindran, Debajyoti Bhattacharyya, George D'Souza, Inderpaul Singh Sehgal, J.K. Samaria, Jogesh Sarma, Lalit Singh, M.K. Sen, Mahendra K. Bainara, Mansi Gupta, Nilkanth T. Awad, Narayan Mishra, Naveed N. Shah, Neetu Jain, Prasanta R. Mohapatra, Parul Mrigpuri, Pawan Tiwari, R. Narasimhan, R. Vijai Kumar, Rajendra Prasad, Rajesh Swarnakar, Rakesh K. Chawla, Rohit Kumar, S. Chakrabarti, Sandeep Katiyar, Saurabh Mittal, Sonam Spalgais, Subhadeep Saha, Surya Kant, V.K. Singh, Vijay Hadda, Vikas Kumar, Virendra Singh, Vishal Chopra & Visweswaran B. (2022) Indian Guidelines on Nebulization Therapy. Indian Journal of Tuberculosis 69, pages S1-S191.
Crossref
Crossref
Nehal E.E. Sayed, Mona A. Abdelrahman & Mohamed E.A. Abdelrahim. (2021) Effect of functional principle, delivery technique, and connection used on aerosol delivery from different nebulizers: An in-vitro study. Pulmonary Pharmacology & Therapeutics 70, pages 102054.
Crossref
Crossref
Felix C. Wiegandt, Ulrich P. Froriep, Fabian Müller, Theodor Doll, Andreas Dietzel & Gerhard Pohlmann. (2021) Breath-Triggered Drug Release System for Preterm Neonates. Pharmaceutics 13:5, pages 657.
Crossref
Crossref
H. Edward DavidsonPeter RadlowskiLisa HanTheresa I. ShiremanCarole DembekXiaoli NiuStefan Gravenstein. (2021) Clinical Characterization of Nursing Facility Residents With Chronic Obstructive Pulmonary Disease. The Senior Care Pharmacist 36:5, pages 248-257.
Crossref
Crossref
Sarah E. Petite, Michael W. Hess & Herbert Wachtel. (2020) The Role of the Pharmacist in Inhaler Selection and Education in Chronic Obstructive Pulmonary Disease. Journal of Pharmacy Technology 37:2, pages 95-106.
Crossref
Crossref
Deepak Talwar, R Ramanathan, Meena Lopez, Rashmi Hegde, Jaideep Gogtay & Geeta Goregaonkar. (2021) The emerging role of nebulization for maintenance treatment of chronic obstructive pulmonary disease at home. Lung India 38:2, pages 168.
Crossref
Crossref
Sheikh Rayees & Inshah DinSheikh Rayees & Inshah Din. 2021. Asthma: Pathophysiology, Herbal and Modern Therapeutic Interventions. Asthma: Pathophysiology, Herbal and Modern Therapeutic Interventions
19
25
.
James F. Donohue, Edward Kerwin, Chris N. Barnes, Edmund J. Moran, Brett Haumann & Glenn D. Crater. (2020) Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis. BMC Pulmonary Medicine 20:1.
Crossref
Crossref
Jill A. Ohar, Andrea Bauer, Sanjay Sharma & Shahin Sanjar. (2020) In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®. Pulmonary Therapy 6:2, pages 289-301.
Crossref
Crossref
Paul D. Terry & Rajiv Dhand. (2020) Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation. Pulmonary Therapy 6:2, pages 177-192.
Crossref
Crossref
Yu. G. Belotserkovskaya. (2020) Рossibilities of clinical application of modern nebulizers. Meditsinskiy sovet = Medical Council:17, pages 50-55.
Crossref
Crossref
Hadeer S. Harb, Haitham Saeed, Yasmin M. Madney, Mona A. Abdelrahman, Hasnaa Osama, Antonio M. Esquinas & Mohamed E.A. Abdelrahim. (2020) Update efficacy of aerosol therapy with noninvasive ventilator approach (non-invasive ventilation and nasal high flow). Journal of Drug Delivery Science and Technology 59, pages 101922.
Crossref
Crossref
Wouter H. van Geffen, Orestes A. Carpaij, Lotte F. Westbroek, Dianne Seigers, Alice Niemeijer, Judith M. Vonk & Huib A.M. Kerstjens. (2020) Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. Respiratory Medicine 171, pages 106064.
Crossref
Crossref
Lei Shi, Armand Gatien Ngounou Wetie, Weimin Wang & Yu‐Luan Chen. (2020) Validation of a sensitive and specific LC–MS/MS method and application to evaluate the systemic exposure and bioavailability of glycopyrrolate via different drug delivery approaches/devices. Biomedical Chromatography 34:9.
Crossref
Crossref
D.V. Dobrianskyi, D.V. Holyshkin, O.V. Los, A. Balatskyi & O. Troshyna. (2020) Investigation of the distribution of particles of drugs with the help of cascade impactor. Infusion & Chemotherapy:2, pages 28-33.
Crossref
Crossref
Mandeep SinghAlexander G. DuarteEn-Shuo HsuYong-Fang KuoGulshan Sharma. (2020) Trends and Factors Associated with Nebulized Therapy Prescription in Older Adults with Chronic Obstructive Pulmonary Disease from 2008 to 2015. Journal of Aerosol Medicine and Pulmonary Drug Delivery 33:3, pages 161-169.
Crossref
Crossref
Sean D. McCarthy, Héctor E. González & Brendan D. Higgins. (2020) Future Trends in Nebulized Therapies for Pulmonary Disease. Journal of Personalized Medicine 10:2, pages 37.
Crossref
Crossref
Andrew R. ClarkJeffry G. WeersRajiv Dhand. (2020) The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates. Journal of Aerosol Medicine and Pulmonary Drug Delivery 33:1, pages 1-11.
Crossref
Crossref
Sanjay Sethi, James F. Donohue, Gary T. Ferguson, Chris N. Barnes & Glenn D. Crater. (2020) Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Therapeutic Advances in Respiratory Disease 14, pages 175346662090527.
Crossref
Crossref
M. G. Matera, C. P. Page, L. Calzetta, P. Rogliani & M. Cazzola. (2019) Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacological Reviews 72:1, pages 218-252.
Crossref
Crossref
Allison Keshishian, Lin Xie, Carole Dembek & Huseyin Yuce. (2019) Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators. Clinical Therapeutics 41:11, pages 2283-2296.
Crossref
Crossref
Greta Adorni, Gerrit Seifert, Francesca Buttini, Gaia Colombo, Luciano A. Stecanella, Irene Krämer & Alessandra Rossi. (2019) Aerosolization Performance of Jet Nebulizers and Biopharmaceutical Aspects. Pharmaceutics 11:8, pages 406.
Crossref
Crossref
Valdecir Castor Galindo-Filho, Luciana Alcoforado, Catarina Rattes, Dulciane Nunes Paiva, Simone Cristina Soares Brandão, James B. Fink & Armèle Dornelas de Andrade. (2019) A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: A randomized controlled trial with radiolabeled aerosols. Respiratory Medicine 153, pages 60-67.
Crossref
Crossref
James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran & Glenn Crater. (2019) Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine 153, pages 38-43.
Crossref
Crossref
Edward M. KerwinJames F. DonohueGary T. FergusonVaidyanathan GanapathyAyca Ozol-GodfreyKrithika Rajagopalan. (2019) Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery 32:1, pages 24-33.
Crossref
Crossref
Ali DabbaghNoor Hayaty Abu KasimChai Hong YeongTin Wui WongNoorsaadah Abdul Rahman. (2018) Critical Parameters for Particle-Based Pulmonary Delivery of Chemotherapeutics. Journal of Aerosol Medicine and Pulmonary Drug Delivery 31:3, pages 139-154.
Crossref
Crossref
Sharath S. Hegde, M. Teresa Pulido-Rios, Mark A. Luttmann, James J. Foley, Gerald E. Hunsberger, Tod Steinfeld, TaeWeon Lee, Yuhua Ji, Mathai M. Mammen & Jeffrey R. Jasper. (2018) Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacology Research & Perspectives 6:3, pages e00400.
Crossref
Crossref
Alpesh N. Amin, Vamsi Bollu, Michael D. Stensland, Logan Netzer & Vaidyanathan Ganapathy. (2018) Treatment patterns for patients hospitalized with chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy 75:6, pages 359-366.
Crossref
Crossref
James F. Donohue, Thomas Goodin, Robert Tosiello & Alistair Wheeler. (2017) Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies. Respiratory Research 18:1.
Crossref
Crossref
Krishna K. Pudi, Chris N. Barnes, Edmund J. Moran, Brett Haumann & Edward Kerwin. (2017) A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respiratory Research 18:1.
Crossref
Crossref
Sohini GhoshJill A. OharM. Bradley Drummond. (2017) Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 30:6, pages 381-387.
Crossref
Crossref
Gary T. Ferguson, Thomas Goodin, Robert Tosiello, Alistair Wheeler & Edward Kerwin. (2017) Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respiratory Medicine 132, pages 251-260.
Crossref
Crossref
Edward Kerwin, James F. Donohue, Thomas Goodin, Robert Tosiello, Alistair Wheeler & Gary T. Ferguson. (2017) Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respiratory Medicine 132, pages 238-250.
Crossref
Crossref
Muhammad H.E. ElHansy, Marina E. Boules, Assem Fouad Mohamed El Essawy, Mohamed Bakry Al-Kholy, Maha M. Abdelrahman, Amira S.A. Said, Raghda R.S. Hussein & Mohamed E. Abdelrahim. (2017) Inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during invasive mechanical ventilation. Pulmonary Pharmacology & Therapeutics 45, pages 159-163.
Crossref
Crossref
Meenakshi Patel, Karl Steinberg, Manuel Suarez-Barcelo, Dana Saffel, Rick Foley & Chad Worz. (2017) Chronic Obstructive Pulmonary Disease in Post-acute/Long-term Care Settings: Seizing Opportunities to Individualize Treatment and Device Selection. Journal of the American Medical Directors Association 18:6, pages 553.e17-553.e22.
Crossref
Crossref
Vamsi Bollu, Annie Guérin, Geneviève Gauthier, Robert Hiscock & Eric Q. Wu. (2016) Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β2-Agonists. Drugs - Real World Outcomes 4:1, pages 33-41.
Crossref
Crossref
Hoda Rabea, Ahmed M.A. Ali, Randa Salah Eldin, Maha M Abdelrahman, Amira S.A. Said & Mohamed E. Abdelrahim. (2017) Modelling of in-vitro and in-vivo performance of aerosol emitted from different vibrating mesh nebulisers in non-invasive ventilation circuit. European Journal of Pharmaceutical Sciences 97, pages 182-191.
Crossref
Crossref
James F. Donohue, Vaidyanathan Ganapathy, Vamsi Bollu, Michael D. Stensland & Lauren M. Nelson. (2017) Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. Clinical Therapeutics 39:1, pages 66-74.
Crossref
Crossref
Ahmed Hassan, Hoda Rabea, Raghda R. S. Hussein, Randa Salah Eldin, Maha M. Abdelrahman, Amira S. A. Said, Heba F. Salem & Mohamed E. Abdelrahim. (2015) In-Vitro Characterization of the Aerosolized Dose During Non-Invasive Automatic Continuous Positive Airway Pressure Ventilation. Pulmonary Therapy 2:1, pages 115-126.
Crossref
Crossref
Mario Cazzola & Paola Rogliani. 2015. Controversies in COPD. Controversies in COPD
213
223
.
Casilda Olveira, Ana Muñoz & Adolfo Domenech. (2014) Terapia nebulizada. Año SEPAR. Archivos de Bronconeumología 50:12, pages 535-545.
Crossref
Crossref
Casilda Olveira, Ana Muñoz & Adolfo Domenech. (2014) Nebulized Therapy. SEPAR Year. Archivos de Bronconeumología (English Edition) 50:12, pages 535-545.
Crossref
Crossref
Zheng ZhuJinping ZhengZhongping WuYanqing XieYi GaoLiping ZhongMei Jiang. (2014) Clinical Practice of Nebulized Therapy in China: A National Questionnaire Survey. Journal of Aerosol Medicine and Pulmonary Drug Delivery 27:5, pages 386-391.
Crossref
Crossref
Timothy E. Albertson, Michael Schivo, Amir A. Zeki, Samuel Louie, Mark E. Sutter, Mark Avdalovic & Andrew L. Chan. (2013) The Pharmacological Approach to the Elderly COPD Patient. Drugs & Aging 30:7, pages 479-502.
Crossref
Crossref